Podcast
Author(s):
We traveled to NewYork City, New York, for a State of the Science Summit™ on Breast Cancer, which focused on the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.
We recently traveled to New York City for a State of the Science Summit™ on Breast Cancer. During the meeting, faculty from the Icahn School of Medicine of Mount Sinai Health System, as well as Columbia University Medical Center, discussed the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
2 Commerce Drive
Cranbury, NJ 08512